跳過瀏覽
體溫計 美國國旗
  • English
  • En Español
  • 繁體中文
  • 越南語

Flu.gov - 了解如何應對流行性感冒。 Flu.gov - 了解如何應對流行性感冒。
  • 流感主頁
  • 新聞,PSA 及推廣活動
  • 您的居住地
  • 常見問題及解答 (FAQ)
  • 針對個人及家庭
    • 關於流感
    • 接種疫苗
    • 預防和治療
    • 家長 (包括準父母)
    • 心理健康和流感
    • 健康狀況欠佳者
    • 年長者
    • 照護人員
    • 旅客
  • 針對專業人士的內容
    • 民間企業策略
    • 社區策略
    • 學校策略
    • 大眾運輸策略
    • 健康專業人員
    • 州政府和地方政府
    • 聯邦政府
    • 全球行動
    • 研究活動

書籤和共享

放大文本字體 缩小文本字體 字體大小 友善列印 友善列印 接收最新消息 接收最新消息 Twitter Twitter Facebook Facebook YouTube YouTube RSS RSS

流感主頁 > 針對專業人士的內容 > Health Professional

給提供者推廣成人肺炎球菌多醣疫苗的公開信

美國東部時間2009 年11月10 日上午11:00

Dear Provider,

We're writing to urge you to make sure all your patients with indications have received the pneumococcal vaccine. Approximately 70 million persons with existing pneumococcal polysaccharide vaccine (PPSV) indications are unvaccinated (National Health Interview Survey, 2007). During the influenza pandemics of the 20th century, secondary bacterial pneumonia was a frequent cause of illness and death and Streptococcus pneumoniae (pneumococcus) was reported as the most common etiology. With the current 2009 H1N1 influenza pandemic, and as with seasonal influenza, pneumococcal infections are once again being found among fatal cases in both children and adults.

During influenza outbreaks, pneumococcal vaccines may be useful in preventing secondary pneumococcal infections. As you know, PPSV is available for prevention of pneumococcal disease among adults and children 2 years of age and older who are at increased risk for pneumococcal disease, but many of those with indications have not yet received the vaccine.  A 7-valent pneumococcal conjugate vaccine is recommended for all children <5 years of age.

CDC's Advisory Committee on Immunization Practices (ACIP) recommends a single dose of PPSV for all people 65 years and older and for persons 2 through 64 years of age with certain high-risk conditions (Box). People in these groups are at increased risk of pneumococcal disease as well as serious complications due to influenza virus infection. A single revaccination with PPSV is recommended at least 5 years after initial vaccination for people 65 years and older who were first vaccinated before age 65. A single revaccination is also recommended for people at highest risk of disease, such as those who have functional and anatomical asplenia, and those who have HIV infection, AIDS or malignancy and have at least five years elapsed from receipt of first vaccination.

All people who have existing indications for PPSV should be vaccinated according to current ACIP recommendations during this 2009-2010 influenza season, which will likely include circulation of both seasonal and 2009 H1N1 influenza viruses. Special emphasis should be placed on vaccinating adults under 65 years of age who have established high-risk conditions; PPSV coverage among this group is very low and this group may be more likely to develop secondary bacterial pneumonia after an influenza infection. Use of PPSV among people without current indications for vaccination is not recommended at this time.

Pneumococcal vaccine may be given at the same time as influenza vaccine. Visits for seasonal and 2009 H1N1 influenza vaccination provide a convenient time to evaluate patients for the need for pneumococcal vaccination. Because the indications for pneumococcal and seasonal influenza vaccines among adults are similar, the need for pneumococcal vaccination should be evaluated at the time of either seasonal influenza vaccination or 2009 H1N1 influenza vaccination. Persons who cannot remember if they've ever had pneumococcal vaccine should still be vaccinated.

Sincerely,

Signature: Anne Schuchat

Anne Schuchat, MD
Director, National Center for Immunization and Respiratory Diseases
美國疾病控制和預防中心

High-Risk Indications for Persons 2 through 64 Years of Age

  • chronic cardiovascular disease (congestive heart failure and cardiomyopathies)
  • chronic pulmonary disease including chronic obstructive pulmonary disease and emphysema
  • diabetes mellitus, alcoholism, chronic liver disease (including cirrhosis)
  • cerebrospinal fluid leaks, cochlear implant
  • functional or anatomic asplenia including sickle cell disease and splenectomy
  • immunocompromising conditions including HIV infection, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, generalized malignancy, chronic renal failure, nephrotic syndrome; those receiving immunosuppressive chemotherapy (including corticosteroids); and those who have received an organ or bone marrow transplant
  • residents of nursing homes or long-term care facilities

High-Risk Indications for Persons 19 through 64 Years of Age

  • smoke cigarettes or have asthma

需要更多資訊

  • 在新型A(H1N1)流感爆發期間,使用23-化合價的肺炎球菌多糖疫苗的因應指導
  • Prevention of pneumococcal infections secondary to seasonal and 2009 H1N1 influenza viruses infection
  • Who needs to be vaccinated with pneumococcal vaccine?
  • Pneumococcal polysaccharide vaccine. Vaccine information statement (VIS)

Last syndicated: March 21, 2010 7:58 PM EDT
本內容由美國疾病控制預防中心 (CDC) 提供

 
  • 主頁
  • 關於我們
  • 聯絡我們
  • 無障礙服務
  • 隱私規則
  • 網站免責聲明
  • WhiteHouse.gov
  • USA.gov
  • GobiernoUSA.gov

White House 美國健康與人員服務部 美國疾病控制和預防中心 美國國土安全部 美國教育部 聯邦商業委員會(FIC) 美國食品和藥物管理局(FDA) 國家健康研究所(NIH)

本聯邦政府網站管理單位: U.S. Department of Health & Human Services - 200 Independence Avenue, S.W. - Washington, D.C. 20201